Pirfenidone Tablet, Film Coated
Product Images NDC 72205-181

9 FDA label images from Novadoz Pharmaceuticals Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 72205-181). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pirfenidone-267mg-270s-carton-label (Pirfenidone 267mg 270s Carton Label)

Pirfenidone-267mg-270s-carton-label (Pirfenidone 267mg 270s Carton Label)
Packaging label for Pirfenidone Tablets 267 mg in a carton containing 270 tablets (9 bottles of 30 tablets each). The label shows the product name, strength, and directions to keep out of reach of children. It is manufactured by MSN Laboratories Private Limited and distributed by Novadoz Pharmaceuticals LLC. The label includes storage instructions and a barcode.*
FDA Label Image

Pirfenidone-267mg-30s-cntr-label (Pirfenidone 267mg 30s Cntr Label)

Pirfenidone-267mg-30s-cntr-label (Pirfenidone 267mg 30s Cntr Label)
Label for Pirfenidone Tablets 267 mg, oral film-coated tablets. The label states the product is prescription only with an NDC of 72205-181-30. The package contains 30 tablets. Manufactured by MSN Laboratories Private Limited in India and distributed by Novadoz Pharmaceuticals LLC. Storage and other instructions are also included beside a barcode.*
FDA Label Image

Pirfenidone-267mg-90s-carton-label (Pirfenidone 267mg 90s Carton Label)

Pirfenidone-267mg-90s-carton-label (Pirfenidone 267mg 90s Carton Label)
Packaging label for Pirfenidone Tablets 267 mg film-coated tablets. The carton contains 90 tablets divided into 3 bottles of 30 tablets each. Manufactured by MSN Laboratories Private Limited, India, and distributed by Novadoz Pharmaceuticals LLC. The label includes storage instructions and a barcode, with a clean white and green design.*
FDA Label Image

Pirfenidone-801mg-30s-cntr-label (Pirfenidone 801mg 30s Cntr Label)

Pirfenidone-801mg-30s-cntr-label (Pirfenidone 801mg 30s Cntr Label)
Label for Pirfenidone Tablets 801 mg, oral film-coated tablets supplied in a 30-tablet package. The label identifies Novadoz Pharmaceuticals LLC as the distributor and MSN Laboratories Private Limited, India as the manufacturer. The label includes storage instructions and product barcodes.*
FDA Label Image

Pirfenidone-801mg-90s-carton-label (Pirfenidone 801mg 90s Carton Label)

Pirfenidone-801mg-90s-carton-label (Pirfenidone 801mg 90s Carton Label)
Packaging label for Pirfenidone Tablets 801 mg oral film-coated tablets by Novadoz Pharmaceuticals LLC. The label indicates a package containing 90 tablets divided into three bottles of 30 tablets each. The label includes storage instructions, manufacturer information, and the National Drug Code (NDC) 72205-182-36.*
FDA Label Image

Fig1 (Pirfenidone Figure 1)

Fig1 (Pirfenidone Figure 1)
A cumulative distribution plot showing the percentage of patients versus absolute change in %FVC (Forced Vital Capacity) from baseline to week 52 for two groups: Pirfenidone (n=278) and Placebo (n=277). The chart distinguishes worsening (decrease in %FVC) from no decline (increase in %FVC) and highlights patient percentages at specific %FVC changes for each group.*
FDA Label Image

Fig2 (Pirfenidone Figure 2)

Fig2 (Pirfenidone Figure 2)
A line graph depicting the mean change in forced vital capacity (FVC) in milliliters over 52 weeks for two groups: one treated with pirfenidone and a placebo group. The graph shows a slower decline in FVC for the pirfenidone group compared to placebo, with data points at weeks 0, 13, 26, 39, and 52.*
FDA Label Image

Fig3 (Pirfenidone Figure 3)

Fig3 (Pirfenidone Figure 3)
A Kaplan-Meier survival curve chart comparing the percentage of patients alive over time (weeks) between Pirfenidone and placebo groups. The chart shows patient numbers at risk at different time points and includes a hazard ratio (HR) with confidence interval indicating survival comparison between the two groups.*
FDA Label Image

Str (Pirfenidone Str)

Str (Pirfenidone Str)
Chemical structure of Pirfenidone, depicting its molecular arrangement with connected aromatic rings, a nitrogen atom, a ketone group, and a methyl substituent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.